Skip to main content

Patient Recruitment

Clinical Research Study for Patients With Hepatocellular Carcinoma

Liver Cancer!

medical illustration of a human liver

close-up of cells

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.

Who Can Participate:

  • 18 years of age or older
  • Diagnosed with advanced HCC
  • Not pregnant or breastfeeding

Study Design:

  • Physical exam and medical history
  • Imaging, such as CT or MRI scan
  • Electrocardiogram (EKG)
  • Patients will receive the study medications every 2- 4 weeks

Location: The NIH Clinical Center, America's Research Hospital is located on the Metro red line (Medical Center stop) in Bethesda, Maryland.

For more information:
NIH Clinical Center Office of Patient Recruitment
800-877-8339 TTY / ASCII
Se habla español

Or go online:
Refer to study # 19-C-0094

Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

NOTE: PDF documents require the free Adobe Reader.

This page last updated on 10/22/2021

You are now leaving the NIH Clinical Center website.

This external link is provided for your convenience to offer additional information. The NIH Clinical Center is not responsible for the availability, content or accuracy of this external site.

The NIH Clinical Center does not endorse, authorize or guarantee the sponsors, information, products or services described or offered at this external site. You will be subject to the destination site’s privacy policy if you follow this link.

More information about the NIH Clinical Center Privacy and Disclaimer policy is available at